Clinical Trials Arena on MSN4d
NiKang concludes first cohort dosing in Phase I trial of NKT3964 for tumours
NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for ...
Hosted on MSN1mon
Jefferies cuts Zentalis stock target to $2.50; maintains hold
Zentalis provided information on the performance of azeno in Phase 1 studies, particularly its objective response rate (ORR) of approximately 30-35% in patients with Cyclin E positive persistent ...
Nature21d
Cyclin' on the viral path to destruction
γ-herpesvirus genomes encode an abundance of homologues of cellular factors, including cyclin and Bcl-2. These viral homologues differ from their cellular counterparts in that the viral proteins ...
manilatimes1mon
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
"We are excited to outline a clear path for Zentalis to bring azenosertib to patients with Cyclin E1+ PROC,” said Ingmar Bruns, M.D., Chief Medical Officer. "In a patient population with a clear unmet ...